[Control of interstitial pneumonia with the application of immune transfer].
Allogeneic bone marrow transplantation (BMT) has been used successfully to treat patients with hematological malignancies. However, interstitial pneumonia has remained a major complication following BMT. We investigated the possibility of immune transfer in recipients treated with BMT from immunized donors. Bone marrow donors were vaccinated with tetanus toxoid (TT) before marrow harvest. After BMT, serum IgG anti-TT antibody titer and in vitro IgG anti-TT antibody production in recipients were assayed sequentially. IgG anti-TT antibody titer in serum increased from about day 20 after BMT. In addition, spontaneous IgG anti-TT antibody producing B cells and TT antigen-specific memory B cells derived from donors were also detected in peripheral blood and bone marrow of recipients from about day 60. We therefore considered that antigen-specific immunity of bone marrow donors is transferable to recipients with BMT, and the immunity continued for a long time in the recipients after BMT. The effectiveness of cytomegalovirus (CMV) vaccine on antibody production was next investigated in healthy adults. Live vaccine induced the production of humoral antibody but envelope vaccine did not. These results indicate that more effective procedure should be needed for the use of envelope vaccine.
Otsuka
M
M
Department of Internal Medicine, Asanogawa General Hospital.
Mori
T
T
D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D003587:Cytomegalovirus / Q000276:immunology*; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007938:Leukemia / Q000601:surgery; D008297:Male; D011658:Pulmonary Fibrosis / Q000517:prevention & control*; D013745:Tetanus Toxoid; D014765:Viral Vaccines
D013745:Tetanus Toxoid; D014765:Viral Vaccines